KRAZATI 200mg film-coated tablets UNIFARM
Chemical substance: adagrasib
ATC code: L01XX77 • Antineoplastic and immunomodulating agents | Other antineoplastic agents
Active substance
Results for the substance adagrasib
1 result
About this active substance
Adagrasib is a medication used in the treatment of certain types of cancer, particularly non-small cell lung cancer (NSCLC) with the KRAS G12C mutation. It is a specific inhibitor of the KRAS G12C mutation, which plays a key role in cancer cell growth and survival.
The medication is taken orally, usually once or twice daily, as directed by a doctor. Adagrasib has shown efficacy in reducing tumor size and slowing disease progression in patients with this specific mutation.
Common side effects include nausea, diarrhea, fatigue, and elevated levels of certain liver enzymes. In rare cases, it may cause severe liver toxicity or other serious adverse reactions.
Patients taking adagrasib should be regularly monitored for liver function and report any side effects or unusual symptoms to their doctor.
The medication is taken orally, usually once or twice daily, as directed by a doctor. Adagrasib has shown efficacy in reducing tumor size and slowing disease progression in patients with this specific mutation.
Common side effects include nausea, diarrhea, fatigue, and elevated levels of certain liver enzymes. In rare cases, it may cause severe liver toxicity or other serious adverse reactions.
Patients taking adagrasib should be regularly monitored for liver function and report any side effects or unusual symptoms to their doctor.